211 related articles for article (PubMed ID: 10155302)
1. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
[TBL] [Abstract][Full Text] [Related]
2. Cost of innovation in the pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
J Health Econ; 1991 Jul; 10(2):107-42. PubMed ID: 10113009
[TBL] [Abstract][Full Text] [Related]
3. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
4. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.
Moore TJ; Zhang H; Anderson G; Alexander GC
JAMA Intern Med; 2018 Nov; 178(11):1451-1457. PubMed ID: 30264133
[TBL] [Abstract][Full Text] [Related]
5. The value of improving the productivity of the drug development process: faster times and better decisions.
DiMasi JA
Pharmacoeconomics; 2002; 20 Suppl 3():1-10. PubMed ID: 12457421
[TBL] [Abstract][Full Text] [Related]
6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
Tay-Teo K; Ilbawi A; Hill SR
JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
[TBL] [Abstract][Full Text] [Related]
8. Innovation in the pharmaceutical industry: New estimates of R&D costs.
DiMasi JA; Grabowski HG; Hansen RW
J Health Econ; 2016 May; 47():20-33. PubMed ID: 26928437
[TBL] [Abstract][Full Text] [Related]
9. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study.
Moore TJ; Heyward J; Anderson G; Alexander GC
BMJ Open; 2020 Jun; 10(6):e038863. PubMed ID: 32532786
[TBL] [Abstract][Full Text] [Related]
10. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V; Mailankody S
JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of a Bayesian model to predict late-phase success of new chemical entities.
Schachter AD; Ramoni MF; Baio G; Roberts TG; Finkelstein SN
Value Health; 2007; 10(5):377-85. PubMed ID: 17888102
[TBL] [Abstract][Full Text] [Related]
12. Key cost drivers of pharmaceutical clinical trials in the United States.
Sertkaya A; Wong HH; Jessup A; Beleche T
Clin Trials; 2016 Apr; 13(2):117-26. PubMed ID: 26908540
[TBL] [Abstract][Full Text] [Related]
13. Rising research and development costs for new drugs in a cost containment environment.
DiMasi JA
Pharmacoeconomics; 1992; 1(Suppl 1):13-20. PubMed ID: 10146926
[TBL] [Abstract][Full Text] [Related]
14. Lasofoxifene: CP 336156, CP-336156.
Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
16. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
Kesselheim AS; Rome BN; Sarpatwari A; Avorn J
Health Aff (Millwood); 2017 Feb; 36(2):362-370. PubMed ID: 28100464
[TBL] [Abstract][Full Text] [Related]
17. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
18. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
Wouters OJ; McKee M; Luyten J
JAMA; 2020 Mar; 323(9):844-853. PubMed ID: 32125404
[TBL] [Abstract][Full Text] [Related]
19. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
20. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
